Staci Sanford joined Golden Eagle Partners after working with David Traylor as a member of the Headwaters Life Science group. Staci has also worked as a healthcare consultant, some of her engagements included: development of a growth strategy for a global pharmaceutical company based on licensing and acquisitions; assessment of the imaging, surgical and histopathology oncology market; creation of a forecasting model for a novel injectable NSAID for use in various indications and under different pricing scenarios; development of a strategy for a global pharmaceutical company to increase market share of a branded generic product; execution of a global assessment of market requirements, adoption criteria and positioning for a molecular diagnostic platform.
Staci received her B.S. degree from Rocky Mountain College, a PhD in Neuroscience from the University of Colorado Health Sciences Center, and a Masters in Finance from the Daniels College of Business at the University of Denver. Her pre- and post-doctoral fellowship research focused on axonal path finding during neurodevelopment, specifically the molecular link between a repellent signal and the growth cone’s turning response away from that signal. Her research has been published in numerous journals such as Molecular Biology of the Cell, European Journal of Neuroscience, and PLoS. Staci has also co-authored a book chapter in Making the Case for Biotechnology.
Staci holds the Series 79 license.
Golden Eagle Partners
Contact David Traylor at firstname.lastname@example.org
Cannabis, Hemp and Life Science Advisors
David Traylor is Senior Managing Director at Golden Eagle Partners, a firm he founded in 2012 to advise life science companies. After advising on various transactions in the life science sector, he took an interest in the cannabis sector and joined Surna, Inc. (OTC:SRNA) as Chief Business Officer in 2014. After close to a year stint at Surna, David re-founded Golden Eagle Partners to provide his knowledge to companies across the cannabis sector.
Before Golden Eagle Partners, David led the Life Science group at Headwaters MB, a leading boutique investment bank. Before Headwaters, David served as a Senior Vice President at Caris & Company where he was focused on biopharmaceuticals. He also previously worked at Pacific Growth Equities, which later became Wedbush. During his banking tenures he has advised private and public biotechnology and medical device companies in various transactions including IPOs, public offerings, private offerings, mergers and acquisitions totaling close to $500 million in value.
Before investment banking, David spent fifteen years in diverse operational roles in biotechnology companies, from research and development to business development, manufacturing, program management and senior management. David began his career in biotechnology, with a position in bioprocess manufacturing at Synergen (acquired by Amgen), and then moved into R&D and process development positions at Somatogen, a company pursuing a recombinant blood substitute. After Somatogen (acquired by Baxter), he led the management of programs and development initiatives at Affymetrix (acquired by Thermo Fisher), the leading innovator in microarray technology. David began his business development career at Deltagen then moved over the lead the U.S. operations for atugen AG (acquired by Silence Therapeutics), a Berlin-based functional genomics company. At Bioseek (acquired by Asterand), David led the business development efforts for one of the first systems biology companies.
David received B.A. degrees from the University of Colorado, Boulder in Biochemistry and Molecular, Cellular and Developmental Biology and an M.B.A. from the Leeds School of Business at the University of Colorado-Boulder. He is also the inventor on three issued U.S. patents.
David holds the Series 7, 63 and 66 securities licenses.
David likes to spend his free time with his wife and two daughters in addition to skiing and lacrosse and other outdoor activities.